Skip to Content
Søk Menu

ASCO 2019: High-risk prostate cancer: 10 year results after image guided intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relateret indhold

Marc Eid og Karl Semaan

Cancer Epigenomics Improve the Overall Survival and the Quality of Life

/ Marc Eid / Karl Semaan
ASCOGU24Prostatakreft Play the Video 1:31

ASCO GU 2024: A Combination of Cabozantinib and Atezolizumab is Promising for Advanced Prostate Cancer Patients with Poor Prognoses

/ Sofie Pohl
ASCOGU24Prostatakreft
Maha H. A. Hussain

Data from the BRCAAway Study Confirms Better PFS & Efficacy with a Combination of Olaparib + Abiraterone Prednisone

/ Maha H. A. Hussain
ASCOGU24Prostatakreft Play the Video 03:10
Neeraj Agarwal

CONTACT-2: Cabozantinib + Atezolizumab for Patients with Metastatic Castration-Resistant Prostate Cancer

/ Neeraj Agarwal
ASCOGU24Prostatakreft Play the Video 05:04
Sophie D. Fosså

Self-Reported Health as a Prognostic Factor in Curative Treatment of Prostate Cancer

/ Sophie D. Fosså
OnkologiskForum23Prostatakreft Play the Video 5:48
Daniel Heinrich

Utvalgte ESMO 2023 Høydepunkter: Prostatakreft

/ Daniel Heinrich
ESMO23Prostatakreft Play the Video 3:31
Henrik Grönberg

Prostate Cancer: Adaptive, Biomarker-Driven Platform Trial Shows That New Hormonal Agents Have Better Efficacy for mCRPC

/ Henrik Grönberg
ESMO23Prostatakreft Play the Video 3:17
Fred Saad

Triplet Therapy with Darolutamide (DARO), Androgen-Deprivation Therapy (ADT) and Docetaxel (DOC) is a Game Changer in the Treatment of Metastatic Hormone-Sensitive Prostate Cancer

/ Fred Saad
ESMO23Prostatakreft Play the Video 3:17
Neal Shore

A Long-Term Benefit of Darolutamide for Patients with nmCRPC

/ Neal Shore
ASCOGU23Prostatakreft Play the Video 4:50
Back to top